within Pharmacolibrary.Drugs.ATC.L;

model L01EF02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.65,
    Cl             = 0.36166666666666664,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 1.09,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00855,
    Tlag           = 24.599999999999998
  );

  annotation(Documentation(
    info ="<html><body><p>Ribociclib is an orally active, selective cyclin-dependent kinase (CDK) 4/6 inhibitor used for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. It is commonly used in combination with endocrine therapies, and is approved for use in multiple regions as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on data from adult patients with advanced breast cancer, both sexes, oral administration under fasting or fed state.</p><h4>References</h4><ol><li>Stefanie L Groenland, Alejandra Martínez-Chávez, Marloes G J van Dongen, Jos H Beijnen, Alfred H Schinkel, Alwin D R Huitema, Neeltje Steeghs,Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.,Clinical pharmacokinetics,2020<a href='https://pubmed.ncbi.nlm.nih.gov/33029704/'>https://pubmed.ncbi.nlm.nih.gov/33029704/</a></li><li>C Louwrens Braal, Elisabeth M Jongbloed, Saskia M Wilting, Ron H J Mathijssen, Stijn L W Koolen, Agnes Jager,Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.,Drugs,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33369721/'>https://pubmed.ncbi.nlm.nih.gov/33369721/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EF02;
